Related Experiment Video
Updated: Dec 5, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Meta-analysis of medical management versus catheter ablation for atrial fibrillation
Yin-Jun Mao1, Hang Wang1, Jian-Xing Chen2
1Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Chazhong Road NO.20, Fuzhou, 350000, Fujian, P. R. China.
Insights
Catheter ablation (CA) offers survival benefits for atrial fibrillation (AF) patients with heart failure and preserved ejection fraction. However, CA
Area of Science:
- Cardiology
- Electrophysiology
- Clinical Trials
Background:
- Observational studies suggest survival benefits of catheter ablation (CA) over medical management (MM) for atrial fibrillation (AF).
- Randomized controlled trial (RCT) data comparing CA and MM for AF treatment remain inconclusive.
Purpose of the Study:
- To conduct a meta-analysis of RCTs evaluating the comparative effectiveness of CA versus MM in AF patients.
- To assess the impact of CA on mortality, hospitalization, arrhythmia recurrence, and stroke risk.
Main Methods:
- Systematic search of Cochrane Library, PubMed, and EMBASE for RCTs comparing AF ablation and MM up to January 2020.
- Meta-analysis of 26 RCTs involving 5788 patients, using risk ratios (RR) and 95% confidence intervals (CI).
Main Results:
- AF ablation demonstrated a mortality benefit in heart failure patients with better left ventricular ejection fraction (LVEF).
- CA increased hospitalization risk as first-line therapy but decreased it as second-line therapy.
- CA effectively reduced atrial arrhythmia recurrence but carried non-negligible complications; stroke risk reduction requires further investigation.
Conclusions:
- Catheter ablation may benefit select AF patients with heart failure and preserved LVEF, particularly in long-term outcomes.
- The role of CA as first- or second-line therapy impacts hospitalization risk.
- Further high-quality RCTs are necessary to definitively establish the long-term stroke risk reduction associated with AF ablation.
Abstract:
Several observational studies have shown a survival benefit for patients with atrial fibrillation (AF) who are treated with catheter ablation (CA) rather than medical management (MM). However, data from randomized controlled trials (RCTs) are uncertain. Therefore, we performed a meta-analysis of RCTs that compared the benefits of CA and MM in treatment of AF. We searched the Cochrane Library, PubMed, and EMBASE databases for RCTs that compared AF ablation with MM from the time of database establishment up to January 2020. The risk ratio (RR) with a 95% confidence interval (CI) was used as a measure treatment effect. Twenty-six RCTs that enrolled a total of 5788 patients were included in the meta-analysis. In this meta-analysis, the effect of AF ablation depended on the baseline level of left ventricular ejection fraction (LVEF) in the heart failure (HF) patients. AF ablation appears to be of benefit to patients with a lesser degree of advanced HF and better LVEF by reducing mortality. Meanwhile, this mortality advantage was manifested in long-term follow-up. CA increased the risk for hospitalization when it was used as first-line therapy and decreased the risk when used as second-line therapy. CA reduced recurrence of atrial arrhythmia for different types of AF (paroxysmal or persistent AF) and CA-related complications were non-negligible. There was no convincing evidence for a reduction in long-term stroke risk after AF ablation, and additional high quality RCTs are needed to address that issue.
Related Concept Videos
Mitral Stenosis III: Medical Management
Dysrhythmias VI: Management of Dysrhythmias
Aortic Regurgitation III: Medical Management
Mitral Regurgitation III: Medical Management
Cardiac Catheterization IV: Nursing Management
Pericarditis III: Medical Management

